Literature DB >> 1717138

Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer.

D Yee1, F R Morales, T C Hamilton, D D Von Hoff.   

Abstract

Insulin-like growth factor (IGF) I is a polypeptide hormone important in normal growth and development. Although IGF-I is a mitogen for many cancer cell lines, previous work has suggested that autocrine production of IGF-I is uncommon in cancers of epithelial origin. In this study, expression of IGF-I, its binding proteins, and its receptor were examined in ovarian cancer cell lines and tissues. Of 10 ovarian cancer cell lines, 3 (OVCAR-3, OVCAR-7, and PEO4) expressed IGF-I mRNA. RNase protection assays using probes derived from IGF-IA, IGF-IB, and alternate exon 1 IGF-I complementary DNAs demonstrated that these cells contained a predominant IGF-I transcript with an alternate first exon. RNA extracted from primary and metastatic ovarian cancer tissues also expressed IGF-I mRNAs (7 of 7) with the alternate first exon. IGF-I protein was detected in OVCAR-3-conditioned media; this activity was secreted in conjunction with several IGF-binding proteins (IGFBPs). IGFBP-2, IGFBP-3, an Mr 24,000 species, and an Mr 30,000 species could also be demonstrated in OVCAR-3. Type I IGF receptor mRNA was found in all 10 of the ovarian cancer cell lines and all 7 of the primary or metastatic ovarian cancer tissues. IGF-I was a mitogen for OVCAR-3, demonstrating the presence of a functional type I IGF receptor. These data show that all the necessary components for an IGF-I-mediated autocrine loop are expressed by ovarian cancer cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717138

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk.

Authors:  Celeste Leigh Pearce; Jennifer A Doherty; David J Van Den Berg; Kirsten Moysich; Chris Hsu; Kara L Cushing-Haugen; David V Conti; Susan J Ramus; Aleksandra Gentry-Maharaj; Usha Menon; Simon A Gayther; Paul D P Pharoah; Honglin Song; Susanne K Kjaer; Estrid Hogdall; Claus Hogdall; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Jacek Gronwald; Krzysztof Medrek; Anna Jakubowska; Jan Lubinski; Georgia Chenevix-Trench; Jonathan Beesley; Penelope M Webb; Andrew Berchuck; Joellen M Schildkraut; Edwin S Iversen; Patricia G Moorman; Christopher K Edlund; Daniel O Stram; Malcolm C Pike; Roberta B Ness; Mary Anne Rossing; Anna H Wu
Journal:  Hum Mol Genet       Date:  2011-03-21       Impact factor: 6.150

2.  The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.

Authors:  Erin R King; Zhifei Zu; Yvonne T M Tsang; Michael T Deavers; Anais Malpica; Samuel C Mok; David M Gershenson; Kwong-Kwok Wong
Journal:  Gynecol Oncol       Date:  2011-07-02       Impact factor: 5.482

3.  Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon.

Authors:  S Freier; O Weiss; M Eran; A Flyvbjerg; R Dahan; I Nephesh; T Safra; E Shiloni; I Raz
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

4.  Is diabetes mellitus a risk factor for ovarian cancer? A case-control study in Utah and Washington (United States).

Authors:  A I Adler; N S Weiss; M L Kamb; J L Lyon
Journal:  Cancer Causes Control       Date:  1996-07       Impact factor: 2.506

5.  Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation?

Authors:  Alberto Fernandez; Niki Karavitaki; Olaf Ansorge; Violet Fazal-Sanderson; John A H Wass
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

6.  Production of insulin-like growth factor binding proteins by human ovarian carcinoma cells.

Authors:  J Hofmann; B Wegmann; R Hackenberg; R Kunzmann; K D Schulz; K Havemann
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 7.  Insulin-like growth factor expression in breast cancer epithelium and stroma.

Authors:  K J Cullen; A Allison; I Martire; M Ellis; C Singer
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

8.  Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.

Authors:  T Yano; J Pinski; G Halmos; K Szepeshazi; K Groot; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

9.  Molecular targeted therapy in advanced renal cell carcinoma: A review of its recent past and a glimpse into the near future.

Authors:  John S P Yuen
Journal:  Indian J Urol       Date:  2009 Oct-Dec

10.  Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer.

Authors:  Marie-Claude Beauchamp; Amber Yasmeen; Ariane Knafo; Walter H Gotlieb
Journal:  J Oncol       Date:  2010-01-05       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.